Advances in clinical chemistry. Volume 66 /
Volume 66 in the internationally acclaimed Advances in Clinical Chemistry contains chapters authored by world renowned clinical laboratory scientists, physicians and research scientists. The serial provides the latest and most up-to-date technologies related to the field of Clinical Chemistry and is...
| Άλλοι συγγραφείς: | |
|---|---|
| Μορφή: | Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Waltham, Massachusetts :
Elsevier,
2014.
|
| Έκδοση: | First edition. |
| Σειρά: | Advances in Clinical Chemistry ;
v. 66. |
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Front Cover; Advances in Clinical Chemistry ; Copyright; Contents; Contributors; Preface; Chapter One: PSA in Screening for Prostate Cancer: More Good than Harm or More Harm than Good?; 1. Introduction; 2. PSA: A Protease with Multiple Isoforms; 3. PSA as a Screening Test for Prostate Cancer; 4. Evaluation of PSA as a Screening Test for Prostate Cancer; 4.1. Randomized prospective trials; 4.2. Systematic reviews and meta-analysis of screening trials; 5. Potential Harms of Prostate Cancer Screening; 6. Attempts to Increase Benefits and Decrease Harms of PSA Screening.
- 7. Attempts to Improve the Accuracy of PSA in Detecting Prostate Cancer7.1. Percent-free PSA (free/total ratio); 7.2. PCA3; 7.3. ProPSA; 7.4. TMPRSS2-ETS fusion mRNA; 7.5. Other emerging markers; 8. Conclusion; References; Chapter Two: Ovarian Cancer Biomarkers: Current State and Future Implications from High-Throughput Technologies; 1. Introduction; 2. Ovarian Cancer; 2.1. Etiology; 2.2. Pathophysiology; 2.3. Clinical management; 2.3.1. Staging and diagnosis of ovarian cancer; 2.3.2. Pelvic mass dilemma; 3. Tumor Markers; 3.1. Types of tumor markers; 3.2. Tumor marker guidelines.
- 3.3. Biomarker development4. FDA-Approved Biomarkers; 4.1. CA125; 4.2. HE4; 4.3. ROMA; 4.4. OVA1; 5. Other Prominent Biomarkers; 5.1. PLCO markers; 5.1.1. Mesothelin; 5.1.2. Interleukin-6 and interleukin-8; 5.1.3. B7-H4; 5.1.4. Osteopontin; 5.1.5. Kallikreins; 5.2. Other markers; 5.2.1. Vascular endothelial growth factor; 5.2.2. Prostasin; 6. Emerging Biomarker Research; 6.1. MicroRNAs; 6.1.1. Diagnosis; 6.1.2. Prognosis; 6.1.3. Therapeutic resistance; 6.2. Targeted proteomics; 6.2.1. Glycomics; 6.2.2. Metabolomics; 6.2.3. Peptidomics; 6.2.4. Autoantibody signatures.
- 6.3. Circulating tumor DNA6.3.1. Pre-NGS Era; 6.3.2. NGS platforms and beyond; 7. Conclusion; References; Chapter Three: Procollagen Assays in Cancer; 1. Introduction; 2. Procollagen Assays: Principles and Methods; 2.1. Type I procollagen; 2.2. Type III procollagen; 3. Fibroproliferation in Healthy Tissues and Cancer; 4. Bone Turnover in Health and Malignant Disease; 5. Effects of Malignant Bone Lesions on Procollagen Propeptides; 5.1. Prostate cancer; 5.2. Breast cancer; 5.3. Other malignancies; 6. Clinical Use of Procollagen Propeptides; 7. Conclusion; References.
- Chapter Four: Metabolomics in Dyslipidemia1. Introduction; 2. Metabolomics; 3. Data Collection; 4. Data Analysis; 5. Hyperlipidemia; 6. Metabolomics in Hyperlipidemia; 6.1. Metabolomics in animal research; 6.1.1. Animal pathologic model research; 6.1.2. Antilipemic agent research; 6.2. Metabolomics in clinical research; 7. Conclusion; Acknowledgments; References; Chapter Five: Metabolism in Chronic Fatigue Syndrome; 1. Introduction; 2. Chronic Fatigue Syndrome; 2.1. Definition; 2.2. Diagnosis and symptoms; 2.3. Epidemiology; 2.3.1. History; 2.3.2. Pathogens and immune system.
